AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $46.38.

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, April 1st. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price for the company. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They set a “buy” rating and a $50.00 target price for the company. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of AnaptysBio in a research report on Friday, May 10th. Finally, BTIG Research assumed coverage on shares of AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 target price for the company.

AnaptysBio Trading Down 2.1 %

NASDAQ:ANAB opened at $22.89 on Thursday. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $27.50. The company’s 50-day moving average is $23.50 and its two-hundred day moving average is $22.79. The firm has a market cap of $625.35 million, a price-to-earnings ratio of -3.73 and a beta of -0.33.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.10). AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The company had revenue of $7.18 million for the quarter, compared to analyst estimates of $4.55 million. On average, equities research analysts forecast that AnaptysBio will post -6.04 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Dennis Mulroy sold 1,500 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the completion of the transaction, the chief financial officer now directly owns 964 shares in the company, valued at approximately $22,866.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Dennis Mulroy sold 1,500 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the transaction, the chief financial officer now directly owns 964 shares in the company, valued at $22,866.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the transaction, the chief executive officer now owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. In the last three months, insiders sold 152,390 shares of company stock worth $3,469,515. 33.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC grew its holdings in AnaptysBio by 0.7% during the fourth quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 500 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio during the first quarter worth about $38,000. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 66.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 2,051 shares during the period. Algert Global LLC grew its holdings in AnaptysBio by 40.2% during the third quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 4,740 shares during the period. Finally, Quest Partners LLC acquired a new position in AnaptysBio during the fourth quarter worth about $119,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.